Source: International journal of gynecological cancer. Unidade: FM
Subjects: NEOPLASIAS OVARIANAS, ANTINEOPLÁSICOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OZA, Amit M. e HEGG, Roberto. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study. International journal of gynecological cancer, v. 27, n. 1, p. 50-58, 2017Tradução . . Disponível em: https://doi.org/10.1097/IGC.0000000000000836. Acesso em: 12 set. 2024.APA
Oza, A. M., & Hegg, R. (2017). Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study. International journal of gynecological cancer, 27( 1), 50-58. doi:10.1097/IGC.0000000000000836NLM
Oza AM, Hegg R. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study [Internet]. International journal of gynecological cancer. 2017 ; 27( 1): 50-58.[citado 2024 set. 12 ] Available from: https://doi.org/10.1097/IGC.0000000000000836Vancouver
Oza AM, Hegg R. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study [Internet]. International journal of gynecological cancer. 2017 ; 27( 1): 50-58.[citado 2024 set. 12 ] Available from: https://doi.org/10.1097/IGC.0000000000000836